China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
read more...
Jan 11, 2021
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
read more...
Jan 11, 2021
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology
read more...
Jan 07, 2021
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference
read more...
Dec 27, 2020
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)
read more...
Dec 07, 2020
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
read more...
Dec 07, 2020
BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH Annual Meeting
read more...
Dec 06, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting
read more...
Dec 01, 2020
BeiGene Announces Pricing of Public Offering by Selling Shareholders
read more...
Dec 01, 2020
BeiGene Launches Proposed Public Offering by Selling Shareholders
read more...
Nov 23, 2020
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
read more...
Nov 19, 2020
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
read more...
Nov 17, 2020
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
read more...
Nov 10, 2020
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China
read more...
Nov 05, 2020
BeiGene Reports Third Quarter 2020 Financial Results
read more...
Nov 05, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting
read more...
Oct 06, 2020
BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071
read more...
Sep 17, 2020
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
read more...
Sep 10, 2020
BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
read more...
Sep 09, 2020
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia
read more...
